CN116138457A - Composite nutritional composition with depression symptom relieving effect - Google Patents

Composite nutritional composition with depression symptom relieving effect Download PDF

Info

Publication number
CN116138457A
CN116138457A CN202211619749.5A CN202211619749A CN116138457A CN 116138457 A CN116138457 A CN 116138457A CN 202211619749 A CN202211619749 A CN 202211619749A CN 116138457 A CN116138457 A CN 116138457A
Authority
CN
China
Prior art keywords
cfu
lactobacillus
depression
composition
mug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202211619749.5A
Other languages
Chinese (zh)
Inventor
单毓娟
刘志鹏
吴超
那冠琼
吴凡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wenzhou Medical University
Original Assignee
Wenzhou Medical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wenzhou Medical University filed Critical Wenzhou Medical University
Priority to CN202211619749.5A priority Critical patent/CN116138457A/en
Publication of CN116138457A publication Critical patent/CN116138457A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Health & Medical Sciences (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention discloses a compound nutritional composition with a depression-like symptom relieving effect, which comprises probiotics, wherein the probiotics are selected from bifidobacterium longum, lactobacillus rhamnosus, lactobacillus casei, lactobacillus fermentum, lactobacillus helveticus and lactococcus lactis subspecies lactis, and also comprises nutrients, wherein the nutrients are selected from folic acid, vitamin B12, selenium, iron and zinc, and the nutrients and the probiotics are mutually combined to relieve the depression-like symptom of mammals. The compound nutritional composition with the function of relieving the depression-like symptoms can relieve the depression-like symptoms of mammals through the combination of probiotics and nutrients.

Description

Composite nutritional composition with depression symptom relieving effect
Technical Field
The invention relates to a composition containing probiotics, in particular to a composite nutritional composition with the effect of relieving depression-like symptoms.
Background
In view of the fact that the occurrence mechanism of depression is not clear, depression patients lack effective drug treatment-the overall curative effect of the treatment group is less than 50%, the recurrence rate of the effective group is 40%, and the drug treatment inevitably causes adverse reactions.
The intestinal microbiota is known as the "second brain" of humans. The intestinal flora interacts not only with the enteric nervous system, but also with the central nervous system via neurological, neuroendocrine, neuroimmune and humoral connections. Among the many different probiotics, one class is known as mental probiotics, which has a beneficial effect on mental health. In addition, the influence of probiotics on the human nervous metabolism can be promoted by the probiotics, so that the normal growth of the probiotics is stimulated, and the intestinal-brain interaction is supported.
Thus, the prior art patent No. 2017800367686, entitled invention of a nutritional composition comprising probiotics for use in the prevention and/or treatment of anxiety and related disorders in mammals, discloses improving synaptic flexibility by increasing the content of at least one of a specific protein Arc (a protein associated with modulation of skeletal activity) and synaptic vesicle proteins present in the hippocampus of the brain. These proteins are better able to adapt in the case of fear, help to regulate the fear experienced during anxiety conditions, and help to prevent fear from occurring later in similar cases, thus achieving regulation in depression, however they do not take into account the important role of nutrients in the neuroendocrine system, the poor nutritional status caused by nutrient deficiency being related to the underlying pathology of behavioural health disorders, and therefore the efficacy of the composition is also somewhat inadequate.
Disclosure of Invention
Aiming at the defects of the prior art, the invention aims to provide a compound nutritional composition with better curative effect and depression symptom relieving effect.
In order to achieve the above purpose, the present invention provides the following technical solutions: a compound nutritional composition with effect of relieving depression-like symptoms comprises probiotics, wherein the probiotics are selected from bifidobacterium longum, lactobacillus rhamnosus, lactobacillus casei, lactobacillus fermentum, lactobacillus helveticus and lactococcus lactis subspecies, and also comprises nutrients, wherein the nutrients are selected from folic acid, vitamin B12, selenium, iron and zinc, and the nutrients and the probiotics are combined with each other to relieve the depression-like symptoms of mammals.
As a further improvement of the invention, a prebiotic is also included, selected from the group consisting of fructooligosaccharides, galactooligosaccharides.
As a further improvement of the present invention, maltodextrin is also included.
As a first improvement of the present invention,
wherein in the probiotic composition, 105-109 CFU/g of bifidobacterium longum, 105-1010 CFU/g of lactobacillus casei, 106-109 CFU/g of lactobacillus helveticus, 107-1010 CFU/g of lactobacillus rhamnosus, 107-109 CFU/g of lactobacillus fermentum and 105-108 CFU/g of lactococcus lactis subspecies lactis;
0.5-4 g of fructo-oligosaccharide and 0.5-4 g of galacto-oligosaccharide in the prebiotic composition;
in the nutrient composition, folic acid 50-100 mug, vitamin B12.1-1.0 mug, selenium 0.5-2.5 mug, iron 1.0-5.0 mg and zinc 0.5-2.5 mg.
As a second modification of the present invention,
wherein in the probiotic composition, bifidobacterium longum is 107-1011 CFU/g, lactobacillus casei is 108-1011 CFU/g, lactobacillus helveticus is 109-1011 CFU/g, lactobacillus rhamnosus is 105-107 CFU/g, lactobacillus fermentum is 109-1012 CFU/g, lactococcus lactis subspecies lactis is 105-108 CFU/g;
4.0-8.0 g of fructo-oligosaccharide and 4.0-8.0 g of galacto-oligosaccharide in the prebiotic composition;
in the nutrient composition, folic acid 100-400 mug, vitamin B12.0-1.2 mug, selenium 2.5-4.0 mug, iron 5.0-10.0 mg and zinc 2.5-5.0 mg.
As a third improvement of the present invention,
wherein in the probiotic composition, 105-108 CFU/g of bifidobacterium longum, 105-108 CFU/g of lactobacillus casei, 104-108 CFU/g of lactobacillus helveticus, 107-1010 CFU/g of lactobacillus rhamnosus, 104-107 CFU/g of lactobacillus fermentum and 109-1010 CFU/g of lactococcus lactis subspecies lactis;
2.0 to 6.0g of fructo-oligosaccharide and 2.0 to 6.0g of galacto-oligosaccharide in the prebiotic composition;
in the nutrient composition, folic acid 20-60 mug, vitamin B12.8-1.5 mug, selenium 4.0-6.0 mug, iron 10.0-12.0 mg and zinc 1.0-4.5 mg.
The invention has the beneficial effects that zinc is taken as a trace element necessary for human body, plays an important role in maintaining the stability of cell membranes, participates in metabolism of more than 300 enzymes, and zinc in the human body mainly exists in brain, especially hippocampus and cerebral cortex. Serious zinc deficiency can lead to common symptoms of neurological diseases and depression, including immune dysfunction, dysphoria, mood changes and cognitive impairment, possibly associated with NMDA receptor antagonism. It was found that zinc deficiency resulted in an increased risk of developing depression, whereas zinc supplementation significantly improved depression-like behaviour. Selenium as an important component of glutathione peroxidase, thioredoxin reductase and selenoprotein P provides protection against lipid peroxidation and oxidative cell damage, and this anti-lipid peroxidation effect of selenium may play a role in its protection against depression. As an important mineral, iron is one of the essential nutrients for the human body, and has a variety of important functions in the body, including the function of iron-containing enzymes, synthesis of bile acids and steroid hormones, and signal control of certain neurotransmitters, such as serotonin and dopamine systems in the brain. In a meta-analysis, high iron intake was found to reduce the chance of depression. Iron deficiency has adverse effects on the psychological health of females and possibly causes depression, so that the effect of relieving depression-like symptoms can be effectively realized by adding nutrients.
Drawings
FIG. 1 is a flow chart of experimental animal feeding;
FIG. 2 is a graph showing the change in body weight and the food consumption rate of mice;
FIG. 3 is a box diagram of OFT experiment results;
FIG. 4 is a box-type diagram of EPM test results;
fig. 5 is a schematic diagram of the immobility time of mice in TST (a) and FST (B).
Detailed Description
The invention will be further described in detail with reference to examples of embodiments shown in the drawings.
The compound nutritional composition with the effect of relieving depression-like symptoms comprises probiotics, wherein the probiotics are selected from bifidobacterium longum, lactobacillus rhamnosus, lactobacillus casei, lactobacillus fermentum, lactobacillus helveticus and lactococcus lactis subspecies lactis, and also comprises nutrients, wherein the nutrients are selected from folic acid, vitamin B12, selenium, iron and zinc, and the nutrients and the probiotics are mutually combined to relieve the depression-like symptoms of mammals.
As an improved embodiment, the composition further comprises a prebiotic selected from the group consisting of fructooligosaccharides, galactooligosaccharides.
As an improved embodiment, maltodextrin is also included.
Specifically, the following example 1 is provided in this example;
wherein in the probiotic composition, 105-109 CFU/g of bifidobacterium longum, 105-1010 CFU/g of lactobacillus casei, 106-109 CFU/g of lactobacillus helveticus, 107-1010 CFU/g of lactobacillus rhamnosus, 107-109 CFU/g of lactobacillus fermentum and 105-108 CFU/g of lactococcus lactis subspecies lactis;
0.5-4 g of fructo-oligosaccharide and 0.5-4 g of galacto-oligosaccharide in the prebiotic composition;
in the nutrient composition, folic acid 50-100 mug, vitamin B12.1-1.0 mug, selenium 0.5-2.5 mug, iron 1.0-5.0 mg and zinc 0.5-2.5 mg.
Specifically, this embodiment also has the following embodiment 2;
wherein in the probiotic composition, bifidobacterium longum is 107-1011 CFU/g, lactobacillus casei is 108-1011 CFU/g, lactobacillus helveticus is 109-1011 CFU/g, lactobacillus rhamnosus is 105-107 CFU/g, lactobacillus fermentum is 109-1012 CFU/g, lactococcus lactis subspecies lactis is 105-108 CFU/g;
4.0-8.0 g of fructo-oligosaccharide and 4.0-8.0 g of galacto-oligosaccharide in the prebiotic composition;
in the nutrient composition, folic acid 100-400 mug, vitamin B12.0-1.2 mug, selenium 2.5-4.0 mug, iron 5.0-10.0 mg and zinc 2.5-5.0 mg.
Specifically, this embodiment also has the following embodiment 3;
wherein in the probiotic composition, 105-108 CFU/g of bifidobacterium longum, 105-108 CFU/g of lactobacillus casei, 104-108 CFU/g of lactobacillus helveticus, 107-1010 CFU/g of lactobacillus rhamnosus, 104-107 CFU/g of lactobacillus fermentum and 109-1010 CFU/g of lactococcus lactis subspecies lactis;
2.0 to 6.0g of fructo-oligosaccharide and 2.0 to 6.0g of galacto-oligosaccharide in the prebiotic composition;
in the nutrient composition, folic acid 20-60 mug, vitamin B12.8-1.5 mug, selenium 4.0-6.0 mug, iron 10.0-12.0 mg and zinc 1.0-4.5 mg.
Experimental procedure and results
1. Design of animal experiment
48 male ICR mice (about 3 weeks old) of 18-22g were purchased, and after 1 week of adaptive feeding, the mice were randomly divided into 6 groups, respectively, a control group, a model group, a nutrient group, a probiotic group and a combination group, which were respectively subjected to gastric lavage (2.0 g/kg.bw/d) using different food formulations, and specific intervention measures are shown in Table 1. After 7 days of continuous intervention, except for the control group, physiological saline is injected into the abdominal cavity, other 5 groups are subjected to depression-like behavior induction by injecting LPS (0.5 mg/kg.bw/d) into the abdominal cavity, and the induction is carried out for 7 days, and intervention of different diet formulas is continued during the induction. Food intake was recorded daily during the experiment, and body weight was weighed and recorded every 3 days. The experiment was started on day 15, and the open field experiment, the overhead plus maze experiment, the tail suspension experiment, the forced swimming and the syrup preference experiment were performed, and the specific animal feeding flow is shown in fig. 2.
TABLE 1 animal intervention for different groups of experiments
Figure SMS_1
2. Behavioural experiments
1) Open field experiment (OFT): reflecting the rejection response and the natural aversion to bright areas generated by mice when exploring new environments. The selected mice were placed in a well lit gray rectangular box (40 cm. Times.40 cm. Times.30 cm) and allowed to move freely within this area. The experiment was initially carried out by placing the mice facing a fixed corner in a small box, then recording the motion trajectories of each mouse with a camera within 6 minutes and generating digitized images, and analyzing the activity behavior for the next 4 minutes.
2) Overhead plus maze test (EPM): the device consisted of two opposing open arms (40 cm. Times.10 cm) and two opposing closed arms (40 cm. Times.10 cm) located 60cm from the ground. At the start of the experiment, mice were placed on a central platform and the activity of the mice (time and number of times the mice entered the open arms, etc.) was recorded during the 5 minute experiment.
3) Tail Suspension Test (TST): in the experiment, the tail of the mice (approximately 1 cm) was stuck with tape and hung in a position where they could not escape or catch the nearby surface (15 cm from the ground). The mice were observed for 6min and the immobility time of the mice was recorded for 4min after.
4) Forced Swimming Test (FST): during the measurement, the mice respond to unavoidable acute stress situations, alternating (floating) between struggling and resting. The animals were placed in a vertical glass cylinder (40 cm high, 15cm in diameter) filled with water at 22-24℃ (30 cm deep). The total duration of stress exposure was 6min, and the mice were left stationary for 4min after recording.
5) Sugar water preference experiment (SPT): the mice were responded to the absence of hedonia. The mice are placed in cages separately to adapt to 24 hours, two drinking bottles are arranged in the cages to respectively contain 1% sucrose solution and water, after water interruption for 12 hours, the two drinking bottles are respectively replaced by l% sucrose solution and water, after 12 hours, the two drinking bottles are respectively weighed (the water bottle is replaced after the middle 6 hours), and the syrup preference rate is calculated. Sugar water preference rate = sucrose solution consumption/(sucrose solution consumption + water consumption).
3. Experimental results
(1) Weight and food consumption rate
The mice were recorded for body weight change (once per 3 days) and food consumption (daily) before the end of the adaptation period to the beginning of the behavioural experiment, and as a result, no significant differences in body weight were found between the mice in the groups during the period (fig. 2A), while only day 9 in food intake were found between the control group and the model group, and no differences were found between the groups at the remaining time points (fig. 2B), indicating that the intervention treatment had no significant effect on both appetite and body weight of the animals.
(2) Behavioral outcome
1)OFT
After the experimental intervention and induction ended, the behavioural experiment was started. OFT was performed on day 15 of the experiment on each group of mice, and as a result, it was found that the number of times the mice in the model group entered the central region (fig. 3A), the residence time (fig. 3B), the movement path length (fig. 3C), and the ratio of the movement path length to the total path length (fig. 3D) were significantly different (P < 0.01), and significantly decreased (P < 0.05), compared to the control group, indicating that the mice after LPS treatment exhibited depression-like behavior. And after the application of the formulation intervention (nutrient, prebiotic, probiotic, or combination formulation), the depressive-like symptoms were alleviated for each group of mice (fig. 3A-D), fig. 3: (a) number of entries into the central region; (B) residence time in the central zone (seconds); (C) moving the path length (cm) in the central region; (D) The movement path in the central region is the ratio (%) of the total path length. The numbers of mice in each group were 6, with # P <0.05 and # P <0.0l indicating significant differences compared to the control group, and P <0.05 and P <0.0l indicating significant differences compared to the model group.
2) EPMOFT was completed and EPM was performed on day 16 of the experiment. As a result, it was found that the model group showed significant differences (P < 0.05) in the number of times of entry into the closed arm (fig. 4A), in the open arm movement distance (fig. 4B) and in the open arm movement time (fig. 4C) compared to the control group, and the control group had a reduced tendency in the open arm/closed arm movement time, indicating that the mice after LPS treatment also showed depression-like behavior; whereas the experimental group mice received various degrees of relief from depression-like symptoms after application of various diet formulas (fig. 4A-D), fig. 4: (a) number of times the closure arm is entered; (B) distance of movement in the open arm; (C) movement time in the open arm; (D) ratio of movement times in the open and closed arms. The numbers of mice in each group were 6, with # P <0.05 and # P <0.0l indicating significant differences compared to the control group, and P <0.05 and P <0.01 indicating significant differences compared to the model group;
3) TST and FST
Two behavioural experiments, TST and FST, were performed on days 17 and 18 respectively after EPM was completed to observe the immobility time of each group of experimental mice. During the experiment, the immobility time of the mice in the model group in TST and FST is significantly higher than that of the mice in the control group (figures 5B, P < 0.05) or has an increasing trend compared with that of the mice in the control group (figure 5A), which shows that the mice in the model group have depression-like behaviors under the influence of LPS, and the depression-like symptoms are significantly relieved under the intervention of various diet formulas (figures 5A and B), and particularly the intervention effect of the mice in the combined group is better. Figure 5 shows the immobility time of mice in TST (a) and FST (B). # P <0.01 indicates significant differences compared to the control group, whereas P <0.05 and P <0.01 indicate significant differences compared to the model group, with 6 mice per group.
From this, it can be seen that
a) Experiments respectively prove that probiotics, prebiotics and nutrients in the formula have anti-depression effects with different degrees when being singly interfered, the effects are better when the probiotics, the prebiotics and the nutrients are combined for intervention, the individual differences are smaller, and the anti-depression agent has universality for large crowds;
b) Compared with the antidepressant products on the market, the raw materials of the formula are convenient and easy to obtain;
c) As a class of food formulations, reference is mainly made to GB 14880-2012, which is safe and has no side effects.
Can be used as an adjuvant treatment food for people with depression or high risk group to improve or prevent depression. The above description is only a preferred embodiment of the present invention, and the protection scope of the present invention is not limited to the above examples, and all technical solutions belonging to the concept of the present invention belong to the protection scope of the present invention. It should be noted that modifications and adaptations to the present invention may occur to one skilled in the art without departing from the principles of the present invention and are intended to be within the scope of the present invention.

Claims (6)

1. A complex nutritional composition having depression-like symptom alleviating effects comprising a probiotic selected from the group consisting of bifidobacterium longum, lactobacillus rhamnosus, lactobacillus casei, lactobacillus fermentum, lactobacillus helveticus, lactococcus lactis subspecies lactis, and characterized in that: the feed additive also comprises nutrients, wherein the nutrients are combinations of folic acid, vitamin B12, selenium, iron and zinc, and the nutrients and probiotics are mutually combined and are used for relieving depression-like symptoms of mammals.
2. The complex nutritional composition having depression-like symptom relieving effect according to claim 1, characterized in that: also included is a prebiotic selected from the group consisting of fructooligosaccharides, galactooligosaccharides, and combinations thereof.
3. The complex nutritional composition having depression-like symptom relieving effect according to claim 2, characterized in that: maltodextrin is also included.
4. A complex nutritional composition with depression-like symptom alleviating effect according to claim 2 or 3, characterized in that:
wherein in the probiotic composition, 105-109 CFU/g of bifidobacterium longum, 105-1010 CFU/g of lactobacillus casei, 106-109 CFU/g of lactobacillus helveticus, 107-1010 CFU/g of lactobacillus rhamnosus, 107-109 CFU/g of lactobacillus fermentum and 105-108 CFU/g of lactococcus lactis subspecies lactis;
0.5-4 g of fructo-oligosaccharide and 0.5-4 g of galacto-oligosaccharide in the prebiotic composition;
in the nutrient composition, folic acid 50-100 mug, vitamin B120.1-1.0 mug, selenium 0.5-2.5 mug, iron 1.0-5.0 mg and zinc 0.5-2.5 mg.
5. A complex nutritional composition with depression-like symptom alleviating effect according to claim 2 or 3, characterized in that:
wherein in the probiotic composition, bifidobacterium longum is 107-1011 CFU/g, lactobacillus casei is 108-1011 CFU/g, lactobacillus helveticus is 109-1011 CFU/g, lactobacillus rhamnosus is 105-107 CFU/g, lactobacillus fermentum is 109-1012 CFU/g, lactococcus lactis subspecies lactis is 105-108 CFU/g;
4.0-8.0 g of fructo-oligosaccharide and 4.0-8.0 g of galacto-oligosaccharide in the prebiotic composition;
in the nutrient composition, folic acid 100-400 mug, vitamin B121.0-1.2 mug, selenium 2.5-4.0 mug, iron 5.0-10.0 mg and zinc 2.5-5.0 mg.
6. A complex nutritional composition with depression-like symptom alleviating effect according to claim 2 or 3, characterized in that:
wherein in the probiotic composition, 105-108 CFU/g of bifidobacterium longum, 105-108 CFU/g of lactobacillus casei, 104-108 CFU/g of lactobacillus helveticus, 107-1010 CFU/g of lactobacillus rhamnosus, 104-107 CFU/g of lactobacillus fermentum and 109-1010 CFU/g of lactococcus lactis subspecies lactis;
2.0 to 6.0g of fructo-oligosaccharide and 2.0 to 6.0g of galacto-oligosaccharide in the prebiotic composition;
in the nutrient composition, folic acid 20-60 mug, vitamin B12 O.8-1.5 mug, selenium 4.0-6.0 mug, iron 10.0-12.0 mg and zinc 1.0-4.5 mg.
CN202211619749.5A 2022-12-14 2022-12-14 Composite nutritional composition with depression symptom relieving effect Pending CN116138457A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202211619749.5A CN116138457A (en) 2022-12-14 2022-12-14 Composite nutritional composition with depression symptom relieving effect

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202211619749.5A CN116138457A (en) 2022-12-14 2022-12-14 Composite nutritional composition with depression symptom relieving effect

Publications (1)

Publication Number Publication Date
CN116138457A true CN116138457A (en) 2023-05-23

Family

ID=86339875

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202211619749.5A Pending CN116138457A (en) 2022-12-14 2022-12-14 Composite nutritional composition with depression symptom relieving effect

Country Status (1)

Country Link
CN (1) CN116138457A (en)

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103200830A (en) * 2010-09-03 2013-07-10 N·V·努特里奇亚 Method and preparation for the treatment or prevention of anxiety or neurogenesis
CN104548099A (en) * 2015-01-12 2015-04-29 陶燃 Anti-depression composition and application thereof
WO2017047777A1 (en) * 2015-09-18 2017-03-23 国立大学法人徳島大学 Serotonin deficiency amelioration agent for after stress-load release
US20170312232A1 (en) * 2014-10-28 2017-11-02 Medlab Ip Pty Ltd Treatment for depression and depressive disorders
CN108403724A (en) * 2018-04-20 2018-08-17 北京斯利安药业有限公司 A kind of composition and preparation method thereof of adjustable mood
WO2018183355A1 (en) * 2017-03-27 2018-10-04 Research Institute At Nationwide Children's Hospital Prebiotic formulations
CN109310716A (en) * 2016-07-01 2019-02-05 雀巢产品技术援助有限公司 For preventing and/or treating the anxiety disorder of mammal and the alimentation composition comprising probiotics of associated disease
CN111728111A (en) * 2020-06-28 2020-10-02 武汉康复得生物科技股份有限公司 Probiotic composition for relieving anxiety or depression and application thereof
CN112999246A (en) * 2021-01-22 2021-06-22 绍兴市第七人民医院 Probiotic composition, and product and application thereof
CN113583923A (en) * 2021-09-28 2021-11-02 中国农业大学 Probiotic composition and application thereof in preparation of medicine for treating constipation and depression
EP3909589A1 (en) * 2020-05-11 2021-11-17 "Jantar" Wody Mineralne Sp z o.o. Liquid probiotic-herbal preparation

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103200830A (en) * 2010-09-03 2013-07-10 N·V·努特里奇亚 Method and preparation for the treatment or prevention of anxiety or neurogenesis
US20170312232A1 (en) * 2014-10-28 2017-11-02 Medlab Ip Pty Ltd Treatment for depression and depressive disorders
CN104548099A (en) * 2015-01-12 2015-04-29 陶燃 Anti-depression composition and application thereof
WO2017047777A1 (en) * 2015-09-18 2017-03-23 国立大学法人徳島大学 Serotonin deficiency amelioration agent for after stress-load release
CN109310716A (en) * 2016-07-01 2019-02-05 雀巢产品技术援助有限公司 For preventing and/or treating the anxiety disorder of mammal and the alimentation composition comprising probiotics of associated disease
WO2018183355A1 (en) * 2017-03-27 2018-10-04 Research Institute At Nationwide Children's Hospital Prebiotic formulations
CN108403724A (en) * 2018-04-20 2018-08-17 北京斯利安药业有限公司 A kind of composition and preparation method thereof of adjustable mood
EP3909589A1 (en) * 2020-05-11 2021-11-17 "Jantar" Wody Mineralne Sp z o.o. Liquid probiotic-herbal preparation
CN111728111A (en) * 2020-06-28 2020-10-02 武汉康复得生物科技股份有限公司 Probiotic composition for relieving anxiety or depression and application thereof
CN112999246A (en) * 2021-01-22 2021-06-22 绍兴市第七人民医院 Probiotic composition, and product and application thereof
CN113583923A (en) * 2021-09-28 2021-11-02 中国农业大学 Probiotic composition and application thereof in preparation of medicine for treating constipation and depression

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
黄莹 等: "益生菌治疗抑郁症效果的meta 分析", 《职业与健康》, vol. 37, no. 7, 1 April 2021 (2021-04-01), pages 962 *

Similar Documents

Publication Publication Date Title
US9034314B2 (en) Nutritional composition comprising probiotics and improving sleep patterns
US20210008130A1 (en) Methods and compositions using bifidobacterium longum to treat or prevent depressive symptoms
EP3478306B1 (en) Nutritional composition comprising a probiotic for the prevention and/or treatment of anxiety disorders and depression in a mammal
AU2019261707B8 (en) Prebiotics for reducing the risk of obesity later in life
JP6329125B2 (en) Stress relieving agent
EP2609814A1 (en) Lactobacillus reuteri DSM 17938 for the development of cognitive function
CN116138457A (en) Composite nutritional composition with depression symptom relieving effect
KR20210102916A (en) Probiotics for Cognitive and Mental Health
EP3344269A1 (en) Methods and compositions using bifidobacterium longum to optimize breastfeeding
AU2014221272B2 (en) A nutritional composition comprising probiotics and improving sleep patterns
CN113332315B (en) Application of bacteroides in preparation of product for preventing and treating Alzheimer disease
US20240058398A1 (en) Composition for improving inflammation of brain tissue
Tewari et al. Probiotics and Gastrointestinal Health: Mechanism of Gastrointestinal Immunomodulation and Neuromodulation
Valmar AnMar Pharma

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination